Policies to stimulate the development of bio-pharmaceutical industry benefit the most

Business News, September 10th, News Biopharmaceuticals: The three areas benefited most clearly from the stem cell industry, monoclonal antibody cloning, and gene recombinant drug testing.

As an important component of the bio-industry, the bio-pharmaceuticals sector again rose strongly under the policy stimulus.

"The market reaction is very obvious, and the impact of the disk drive is very great." Peng Yunliang, an analyst at the Shanghai securities and pharmaceutical industry, said in an interview with the "First Financial Daily" yesterday that the biopharmaceutical industry has been doing very well in the recent past, driven by related positive trends.

In 2009, the output value of China's pharmaceutical industry exceeded the trillion mark for the first time, an increase of 30% year-on-year. At the same time, however, the Chinese pharmaceutical industry has not escaped the status quo of more generic but not strong generic drugs.

In this regard, Yu Mingde, president of the China Association of Pharmaceutical Industry Management, believes that due to the slowing global economic development and the rising costs of innovative drug research and development, coupled with the expiration of a large number of international patents, domestic companies should step up efforts in research and development of new drugs, and take the opportunity to develop new drugs. Make a difference.

More than that, because of the current export of pharmaceutical products in China, mainly bulk bulk drugs, relative to the variety of preparations, raw materials, high pollution, high energy consumption, the cost of economic development is huge, and due to the low value of the industry chain, the added value is also very low. Therefore, the development of high-tech preparations represented by biomedicine is particularly urgent in the context of economic restructuring.

“According to successive documents, biomedicine may become the most obvious benefit, and three of these areas will be the most obvious at present.” Peng Yunliang told the newspaper that as the first major project of the national new drug creation plan, The stem cell industry will be greatly stimulated, and the monoclonal antibody cloning and gene recombination drug detection will also become the country's key support for the biopharmaceutical industry. Due to the contribution of early detection of the disease, recombinant drug detection is now included in the Development and Reform Commission related to the industrial development planning directory.

It is reported that North China Pharmaceutical (600812.SH) and Hisun Pharmaceutical (600267.SH) have been conducting research for artificial recombinant albumin for many years; Lunan Pharmaceutical, Hengrui Pharmaceutical (600276.SH), Xiansheng Pharmaceutical ( SCR.NYSE) has also worked on the establishment of variety pharmaceuticals and product standards.

Earlier, there was news that the biomedical industry revitalization plan led by the National Development and Reform Commission had been completed by the end of August. It is currently in the consultation stage and is expected to be finally announced between October and November.

Under the guidance of the national policy, the local industry-led policies have gradually been announced.

According to the “Outline of the Development Plan for Biotechnology and New Pharmaceutical Industry in Jiangsu Province (2009-2012)” released recently, the pharmaceutical province of Jiangsu has identified Taizhou as the province’s biopharmaceutical platform – until 2012, Taizhou aims to A 50 billion yuan biopharmaceutical industry scale will be established, and five major industrial bases for biological vaccines, new preparations, biopharmaceuticals, digital medical devices, and proprietary Chinese medicines will be established. The construction of the China Vaccine Engineering Center will be promoted, and protein drugs and genetic engineering drugs will be developed. The emerging biomedical industry represented.

The Yangtze River, Jiangsu Hengrui and other companies that radiate from Taizhou as the center will undoubtedly benefit from the national and local policies at the two levels.

Acord Pharmaceutical (000028.SZ) recently announced that its actual controller, China National Pharmaceutical Group, has recently signed a strategic cooperation framework agreement with the Shenzhen Municipal People's Government, relying on Sinopharm Group's R&D advantages in the pharmaceutical industry to leverage the Shenzhen government's strong support for the development of the biopharmaceutical industry. The opportunity was to establish a South China Biopharmaceutical R&D Center and a South China Biopharmaceutical Industry Research and Development Alliance in Shenzhen to jointly create an incubator for the development of Shenzhen's biopharmaceutical industry, and conduct various forms of cooperation in drug R&D and design.

Zhang Xiaoqiang, deputy director of the National Development and Reform Commission, revealed that “in the biomedical industry revitalization plan, the clustering and internationalization of bio-industries will be promoted, and the focus of the future development of the bio-pharmaceutical industry will fall on the internationalization strategy.” Thus, plans will be issued after Vigorously promote the development of China's biomedical industry toward internationalization.

According to statistics from the China Chamber of Commerce for Import and Export Commerce, from January to June 2010, domestic exports of biochemical drugs amounted to US$1.032 billion, an increase of 65.07% year-on-year.

Zhang Xiaoqiang once said publicly: “As far as bio-medicine is concerned, in the 12th Five-Year Plan for Bio-pharmaceutical Industry Revitalization, it will focus on promoting the industrialization of bio-technology with independent intellectual property rights and promoting the clustering and internationalization of bio-industries.”